Dawn C. Buse
Albert Einstein College of Medicine
EpidemiologyPsychiatryInternal medicineOdds ratioPsychologyHealth carePhysical therapyPediatricsTriptansMigraineDepression (differential diagnoses)ComorbidityInternational Classification of Headache DisordersPopulationChronic MigraineEpisodic migraineFamily medicineAnxietyClinical psychologyMedicine
256Publications
53H-index
7,799Citations
Publications 258
Newest
#1James S. McGinleyH-Index: 3
#2Andrea Savord (ASU: Arizona State University)
Last. Dawn C. Buse (Albert Einstein College of Medicine)H-Index: 53
view all 6 authors...
In recent years, emphasis has been placed on conducting headache research that is patient-centered to more explicitly incorporate the input of people who live with headache diseases. The Growing Up with Migraine Study was developed with this intention using a two-step process: 1. develop and administer a survey to identify research areas that matter most to people with adolescent migraine and/or their caregivers and 2. use the survey results to guide future secondary data analyses. This brief re...
Source
#2Xiaoping NingH-Index: 3
Last. Dawn C. Buse (Albert Einstein College of Medicine)H-Index: 53
view all 6 authors...
Background null Migraine is associated with depression as well as negative impact on quality of life and work productivity. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. null Objective null In this open-label extension (OLE) of the phase 3b FOCUS study, we assessed patient-reported outcomes (PROs) over time. null Methods null Patients with episodic migraine (E...
Source
#1Rebecca Erwin Wells (Wake Forest Baptist Medical Center)H-Index: 17
#2Paige M. Estave (Wake Forest Baptist Medical Center)H-Index: 1
Last. Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
view all 8 authors...
Source
#1Paige M. Estave (Wake Forest Baptist Medical Center)H-Index: 1
#2Summerlyn Beeghly (Wake Forest Baptist Medical Center)
Last. Rebecca Erwin Wells (Wake Forest Baptist Medical Center)H-Index: 17
view all 15 authors...
OBJECTIVE To better characterize the ways that migraine affects multiple domains of life. BACKGROUND Further understanding of migraine burden is needed. METHODS Adults with migraine randomized to mindfulness-based stress reduction or headache education arms (n = 81) in two separate randomized clinical trials participated in semistructured in-person qualitative interviews conducted after the interventions. Interviews queried participants on migraine impact on life and were audio-recorded, transcr...
1 CitationsSource
#1Ryan J Diel (UIHC: University of Iowa Hospitals and Clinics)H-Index: 2
#2Divy Mehra (Bascom Palmer Eye Institute)H-Index: 3
Last. Anat Galor (Bascom Palmer Eye Institute)H-Index: 37
view all 6 authors...
Background Photophobia is a potentially debilitating symptom often found in dry eye disease (DE), migraine and traumatic brain injury (TBI). Methods We conducted a review of the literature via a PubMed search of English language articles with a focus on how photophobia may relate to a shared pathophysiology across DE, migraine and TBI. Results DE, migraine and TBI are common conditions in the general population, are often comorbid, and share photophobia as a symptom. Across the three conditions,...
7 CitationsSource
#1Richard B. Lipton (Montefiore Medical Center)H-Index: 178
#2Rami Burstein (Harvard University)H-Index: 76
Last. Denise E. Chou (Amgen)H-Index: 5
view all 8 authors...
BACKGROUND Ictal cutaneous allodynia, common in chronic migraine, is associated with reduced responses to acute treatment with triptans. Allodynia's impact on the efficacy of newer preventive treatments such as erenumab is unknown. METHODS Post-hoc subgroup analysis of a double-blind, randomized, placebo-controlled 12-week study of erenumab in chronic migraine, contrasting those with no allodynia with those with moderate-severe allodynia assessed with the Allodynia Symptom Checklist-12, was unde...
1 CitationsSource
#1Messoud AshinaH-Index: 65
#2Dawn C. Buse (Albert Einstein College of Medicine)H-Index: 53
Last. David W. Dodick (Mayo Clinic)H-Index: 94
view all 12 authors...
Summary Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable info...
10 CitationsSource
#1Messoud AshinaH-Index: 65
#2Zaza Katsarava (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
Last. Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
view all 15 authors...
Summary Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies. In this Series paper, we summarise the data on migrai...
14 CitationsSource
#1Richard B. LiptonH-Index: 178
#2Dawn C. BuseH-Index: 53
Last. Todd J. SchwedtH-Index: 37
view all 3 authors...
We thank Dr. Minen for her comment on our article,1 and we agree that additional training and education in headache management is needed for ED/UC physicians and pain specialists. Furthermore, we are encouraged by the community-led efforts to facilitate education on migraine and headache management.
1 CitationsSource
#1Dionne M. HinesH-Index: 5
#2Shweta Shah (Amgen)H-Index: 3
Last. Mark Bensink (Amgen)H-Index: 15
view all 6 authors...
OBJECTIVE To describe patient characteristics, adherence, and treatment patterns, among adult migraine patients in the United States prescribed erenumab. BACKGROUND Migraine is a highly prevalent and debilitating disease characterized by recurrent attacks of moderate to severe headache accompanied by non-headache symptoms. Erenumab is a first-in-class calcitonin gene-related peptide receptor (CGRP-R) antagonist indicated for migraine prophylaxis in adults. METHODS This retrospective longitudinal...
2 CitationsSource